ICYMI: SRP-9003 Study Shows Positive Results for Treating LGMD Type 2E
27707 / Pixabay

ICYMI: SRP-9003 Study Shows Positive Results for Treating LGMD Type 2E

  In a recent press release, biotechnology company Sarepta Therapeutics announced positive findings from their clinical trial studying SRP-9003 as a treatment for limb-girdle muscular dystrophy (LGMD) type 2E. This…

Continue Reading ICYMI: SRP-9003 Study Shows Positive Results for Treating LGMD Type 2E
Close Menu